Last reviewed · How we verify
minoxidil + finasteride
Minoxidil stimulates hair growth by prolonging the anagen phase and improving blood flow to hair follicles, while finasteride inhibits 5-alpha reductase to reduce DHT-mediated hair loss.
Minoxidil stimulates hair growth by prolonging the anagen phase and improving blood flow to hair follicles, while finasteride inhibits 5-alpha reductase to reduce DHT-mediated hair loss. Used for Androgenetic alopecia (male pattern baldness), Hair loss in men.
At a glance
| Generic name | minoxidil + finasteride |
|---|---|
| Sponsor | Beijing Dayspring Pharmaceutical Technology Co., Ltd |
| Drug class | Combination antialopecia agent |
| Target | Potassium channels (minoxidil); 5-alpha reductase type II (finasteride) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and extends the growth phase of the hair cycle. Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting 5-alpha reductase, reducing the androgenic signal that causes hair follicle miniaturization in male pattern baldness. Together, they address hair loss through complementary mechanisms.
Approved indications
- Androgenetic alopecia (male pattern baldness)
- Hair loss in men
Common side effects
- Scalp irritation or dermatitis (minoxidil)
- Sexual dysfunction or decreased libido (finasteride)
- Dizziness or lightheadedness (minoxidil)
- Gynecomastia (finasteride)
- Hypertrichosis (minoxidil)
Key clinical trials
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE2)
- Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia (PHASE3)
- Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE1)
- Various Procedural Treatment Options for Androgenetic Alopecia (PHASE2)
- Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia (PHASE2, PHASE3)
- Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia (PHASE1)
- The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- minoxidil + finasteride CI brief — competitive landscape report
- minoxidil + finasteride updates RSS · CI watch RSS
- Beijing Dayspring Pharmaceutical Technology Co., Ltd portfolio CI